Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23522762 | 1.00 | HTR2C (0.40) | HTR2CPARP1PARP2KDM1ARCOR1 | |
| SCHEMBL23522761 | 1.00 | HTR2C (0.40) | HTR2CPARP1PARP2KDM1ARCOR1 | |
| SCHEMBL23545798 | 0.82 | HTR2C (0.46) | HTR2CKDM1ARCOR1 | |
| SCHEMBL23123726 | 0.81 | KDM1A (0.33) | KDM1ACA1 | |
| SCHEMBL24700456 | 0.81 | KDM1A (0.33) | KDM1ACA1 | |
| SCHEMBL24700455 | 0.81 | KDM1A (0.33) | KDM1ACA1 | |
| SCHEMBL23123313 | 0.81 | KDM1A (0.33) | KDM1ACA1 | |
| SCHEMBL24541167 | 0.81 | L3MBTL1 (0.40) | KDM1ARCOR1L3MBTL1 | |
| SCHEMBL24541168 | 0.81 | L3MBTL1 (0.40) | KDM1ARCOR1L3MBTL1 | |
| SCHEMBL24541166 | 0.81 | L3MBTL1 (0.40) | KDM1ARCOR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | HTR2C 4792/4885PARP1 433/4885PARP2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.